Tiziana Life Sciences has shared positive three-month neuroimaging scores in non-active secondary progressive multiple sclerosis (na-SPMS) patients receiving intranasal foralumab. Affecting ...
Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt) has been approved by the US Food and Drug Administration (FDA) to treat ...
Johnson & Johnson’s (J&J) Rybrevant (amivantamab) in combination with chemotherapy, has been recommended by the European ...
Regeneron Pharmaceuticals and Mammoth Biosciences have announced a collaboration aimed at developing CRISPR-based gene ...
Up to 40% of patients who have undergone definitive prostate cancer treatment will experience biochemical recurrence within ...
Biogen has announced that Tofidence (tocilizumab-bavi), a biosimilar referencing Roche’s RoActemra, has been recommended by ...
The BCMA-targeted therapy is the first to receive approval in Europe for RRMM patients as early as first relapse ...
Xaira Therapeutics, a new biotech aiming to “re-engineer” drug discovery and development using artificial intelligence (AI), ...
Novartis’ radioligand therapy Lutathera (lutetium Lu 177 dotatate) has been approved by the US Food and Drug Administration ...
With 14 million people in Europe expected to suffer from Alzheimer’s and other forms of dementia by 2030, the race is on to find a treatment to not only slow its course, but even prevent the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results